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The purpose of this study is to determine whether esophageal varices (EV) can be identified through 
the evaluation of spleen stiffness (SSM) via acoustic radiation force impulse (ARFI). A total of 135 
patients suffering from cirrhosis underwent a clinical exam, laboratory tests, abdominal ultrasound, 
liver stiffness (LSM) measurement, SSM evaluation and upper gastrointestinal endoscopy. Based 
on the endoscopy results, the patients were classified into three groups: those with no evident 
EV, those with small EV and those with varices needing treatment (VNT). Patients with EV of any 
grade had significantly higher average SSM values over those with no EV (3.37 m/s versus 2.79 m/s, 
p-value < 0.001), while patients with VNT showed an even greater difference (3.96 m/s versus 2.93 m/s, 
p-value < 0.001). SSM proved to be an excellent method of predicting patients with VNT.
Currently, patients suffering from cirrhosis are recommended upper gastrointestinal endoscopy (UGE) screening, 
in order to detect esophageal varices (EV). Unfortunately, UGE is an expensive, time-consuming method that is 
not well tolerated by patients. Consequently, various non-invasive methods of diagnosing EV have recently been 
proposed, the most promising one being the measuring of spleen stiffness (SSM). Our study proved that SSM, 
measured through acoustic radiation force impulse elastography, can consistently predict large EVs in cirrhotic 
patients, including those with a high risk of bleeding. Those with a higher bleeding risk are currently categorized 
as varices needing treatment (VNT) in the expanded Baveno VI guidelines. Our study proposes SSM as an alter-
native method for ruling out patients with VNT. This avoids the need for upper GI endoscopy, thus improving 
upon the Baveno VI criteria.
Portal hypertension (PH) as well as esophageal varices are major aggravations of hepatic cirrhosis, which are 
associated with increased mortality rates1,2. The gold standard method for measuring PH is the hepatic pressure 
venous gradient (HPVG), whilst the diagnosis of EV requires upper endoscopy3,4. Both of these investigations are 
invasive, not always well tolerated by patients, expensive, difficult to repeat and HPVG is also not widely available. 
Therefore, the need for noninvasive tools that accurately predict the presence and severity of PH and EV is crucial 
to help perform a proper prophylaxis of variceal bleeding5–7.
PH leads to splenic congestion, which induces architectural changes in the splenic arteries and veins, resulting 
in fibrosis and an increase in spleen stiffness (SSM)5,8. Recently, noninvasive techniques that measure SSM, in 
order to identify EVs and their hemorrhage risk are gaining more and more interest5,7,9–12. SSM can be evaluated 
through elastography techniques, such as shear wave elastography (SWE)13, transient elastography (TE)14, strain 
elastography and acoustic radiation force impulse (ARFI)15. These techniques are accurate in predicting the exist-
ence of EVs in most cases of cirrhosis with portal hypertension, including both viral and alcoholic cirrhosis16–19. 
TE is a useful method to detect high risk EVs, although it is limited by factors such as obesity and the ascites5,20. 
SWE is another good diagnostic method for those with clinically significant PH21,22.
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Nevertheless, one of the most studied elastography techniques is ARFI, a new alternative investigation that 
evaluates tissue elasticity and that is reliable even in cases associating obesity or ascites5,6. ARFI is categorized 
as a displacement imaging technique, which uses a deep focused radiation force, induced by ultrasound. This 
measures the stiffness of a tissue, both quantitatively and qualitatively. The displacement is measured by compar-
ing the locations of tissue echoes emitted before and immediately after the impulse15. Our study aimed to assess 
the clinical use of splenic stiffness (SSM), evaluated through ARFI, in patients suffering from cirrhosis. This was 
conducted in order to predict the existence and gravity of esophageal varices.
Materials and Methods
Study design. Our prospective study was performed on a series of patients with compensated cirrhosis 
from the Gastroenterology Department at the Bucharest Emergency University Hospital, between October 2016 
and September 2017. The exclusion criteria included: decompensated cirrhosis (as evaluated by the presence of 
ascites, hepatic encephalopathy and the Child-Pugh Score), current treatment with beta blockers and previous or 
current variceal bleeding. The diagnosis of cirrhosis was established based on a combination of results from the 
clinical exam, laboratory blood tests, abdominal ultrasound and upper gastrointestinal endoscopy. Either positive 
histology from hepatic biopsy or LSM > 10 kPa on TE were required as inclusion criteria.
A study protocol was respected for each patient, which included a clinical exam, laboratory tests (hemogram, 
hepatic panel, serum albumin), abdominal ultrasound (highlighting the spleen diameter, portal vein diameter as 
well as the existence of ascites), liver and spleen ARFI elastography and upper gastrointestinal endoscopy. All tests 
were conducted within a maximum of 72 hours from each other. All methods were performed in accordance with 
the relevant institutional and national guidelines and regulations23,24. The study was approved by the Local Ethics 
Committee and informed consent forms were signed by each patient.
Elastography measurement. Acoustic Radiation Force Imaging (ARFI) elastography was performed on 
each patient, after at least 12 hours of fasting, using the Siemens Acuson S2000 (Siemens AG) device and a dual 
B-mode ultrasound and quantitative elastography convex probe (Siemens 4C1). In order to conduct the measure-
ments each patient was asked to hold his or her breath for 5 seconds. We carried out two separate sets of measure-
ments – LSM and SSM respectively. Measurement sites were chosen 2 cm beneath the capsule of each organ. Each 
set of measurements was repeated at least ten times and the average value was chosen.
Esophageal varices classification. Esophageal varices were evaluated for each patient, using upper gastro-
intestinal endoscopy and were classified into three groups, according to the expanded Baveno VI criteria25. Group 
1 included patients with no esophageal varices, Group 2 – patients with low risk esophageal varices (varices that 
had a thickness of less than 5 mm) and Group 3 – patients with varices needing treatment (VNT – either large 
esophageal varices that had a thickness of more than 5 mm or varices displaying any signs of a high risk of bleed-
ing: red wales, cherry red spots).
Statistical analysis. The results were inputted into a table using Microsoft Excel (Microsoft Corporation) 
and analyzed using Microsoft Excel, SPSS Version 23 (IBM Corporation) and MedCalc 19. The normality of 
the variables was assessed using histograms and the Shapiro-Wilk test. Univariate analysis for parameters with 
normal distribution was assessed using Independent Samples T Test, while for the parameters without normal 
distribution the Independent Samples Mann-Whitney U Test (for two categories) and Independent Samples 
Kruskal-Wallis Test (for more than two categories) were used. Multivariate analysis was performed using binary 
logistic regression. For each parameter, we assessed not only sensitivity and specificity, but also positive and neg-
ative predictive values, and positive and negative likelihood ratios at three distinct cut-off points – a cut-off based 
on the highest Youden’s J statistic point, a rule out cut-off (best negative likelihood ratio) and a rule in cut-off (best 
positive likelihood ratio). Cut-off values were selected based on the ROC curve and overall accuracy was deter-
mined using the area under the curve (AUROC). The strength of associations was calculated using the Spearman 
Rho test and multivariate analysis was performed on all parameters associated in univariate analysis. A p-value 
of <0.05 was considered statistically significant for all tests. The area under the ROC curve was interpreted as 
insignificant for results between 0.500–0.600, a poor predictor for results 0.600–0.700, a fair predictor for results 
0.700–0.800, a good predictor for results 0.800–0.900 and an excellent predictor for results >0.900. The compar-
ison between ROC curves was performed using the DeLong test, as illustrated in Fig. 1.
Results
Characteristics of patients. The study included a total number of 135 patients, out of which 77 were 
male and 58 were female. The patients were evenly distributed by age and gender, with no statistical difference 
between the groups. The etiology of cirrhosis was alcoholic (33 patients), hepatitis B (20 patients), hepatitis C 
(76), cryptogenic (5 patients) and primary biliary cirrhosis (1 patient). All enrolled patients were included in the 
study. Bivariate analysis identified several factors that were associated with the size of varices, including aspar-
tate aminotransferase (p = 0.001), platelet count (p < 0.001), spleen diameter (p < 0.001), portal vein diameter 
(p < 0.001), liver elastography (p < 0.001) and spleen elastography (p < 0.001), as listed in Table 1.
Diagnostic performance of spleen stiffness. There is a stepwise increase in spleen stiffness values 
correlated with an increased severity of portal hypertension. Patients with esophageal varices of any grade had 
significantly higher average spleen elastography values than those with no varices (3.37 m/s versus 2.79 m/s, 
p-value < 0.001), while those with varices needing treatment had an even greater difference versus patients with 
no or small varices (3.96 m/s versus 2.93 m/s, p-value < 0.001). AUROC values were fair for the detection of any 
degree of esophageal varices (AUROC = 0.776, 95% CI = 0.698–0.853, p < 0.001) and excellent at distinguishing 
patients with varices needing treatment (AUROC = 0. 972, 95% CI = 0. 944–1.000, p < 0.001). The results of 
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the liver elastography were poor for the detection of any degree of esophageal varices (AUROC = 0.682, 95% 
CI = 0.586–0.777, p < 0.001) and fair for distinguishing patients with varices needing treatment (AUROC = 0. 
712, 95% CI = 0. 613–0.812, p < 0.001). The results of the splenic elastography were superior for varices needing 
treatment (p < 0.0001), but were not statistically significant for the diagnosis of any varices (p = 0.0768). The 
accuracy of spleen elastography for each test is detailed further in Table 2. The Spearman correlation test showed a 
stronger association for spleen elastography (r = 0.461, p < 0.001 for any grades of varices and r = 0.671, p < 0.001 
for varices needing treatment) than any other investigated parameters, including liver elastography (which was 
second best, with a more modest r = 0.304, p < 0.001 for any grades of varices and r = 0.302, p < 0.001 for varices 
needing treatment). In the case of varices needing treatment, the variation of accuracy depending on prevalence 
is illustrated in Table 3. The multivariate analysis showed that spleen elastography was the sole parameter that was 
precisely correlated not only with the signs of an elevated risk of bleeding, but also with the existence of varices, 
irrespective of grade (p-values are presented in Table 4). The various etiologies of cirrhosis did not influence the 
spleen elastography results in our study (Table 5).
Discussions
One of the major complications of cirrhosis, regardless of its etiology is portal hypertension, a frequent cause 
of death for cirrhotic patients. Clinically significant portal hypertension (CSPH, hepatic venous pressure gra-
dient ≥ 10 mmHg) is the main cause of cirrhosis decompensation and it can influence the survival of cirrhotic 
patients. The complications of CSPH include ascites, hepatic encephalopathy and bleeding from gastroesophageal 
varices, which is still associated with a high mortality rate of 10–20%4 at six weeks. Therefore, the assessment 
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Figure 1. ROC curves for spleen elastography.
No Varices
(n = 50, 44%)
Small Varices 
(n = 36, 31%)
Varices Needing 
Treatment (n = 29, 25%) p-value
Age 60.16 ± 10.16 57.61 ± 7.14 62.89 ± 9.82 0.091
Gender 23 F27 M
14 F
22 M
14 F
15 M 0.733
Aspartate Aminotransferase 51.36 ± 38.21 48.44 ± 24.30 69.79 ± 26.95 0.001
Alanine Aminotransferase 44.66 ± 21.86 53.5 ± 28.81 56.51 ± 32.25 0.347
Platelet Count 188082 ± 70432 155958 ± 88680 102175 ± 47657  < 0.001
Spleen Diameter 110.96 ± 19.67 126.69 ± 22.58 141.69 ± 22.74  < 0.001
Portal Vein Diameter 10.16 ± 1.96 10.49 ± 1.68 11.69 ± 1.84  < 0.001
Hemoglobin 13.16 ± 1.25 13.28 ± 1.17 12.33 ± 1.79 0.210
Liver Elastography 2.00 ± 0.51 2.19 ± 0.54 2.55 ± 0.57  < 0.001
Spleen Elastography 2.79 ± 0.41 3.02 ± 0.40 3.96 ± 0.37 < 0.001
Table 1. Patient characteristics and univariate analysis.
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of portal pressure is a constant concern that influences the outcomes in both stages of cirrhosis: compensated 
or decompensated. HVPG and upper endoscopy are the gold-standard techniques for the diagnosis of portal 
hypertension and esophageal varices. However, their invasiveness makes them rarely accepted by patients. The 
non-invasive tests are able to provide similar information and are more welcomed. Previous studies, that have 
used HVPG as a reference, have shown a significant association between the LSM values and the risk of portal 
hypertension development in cirrhotic patients, by assessing the liver stiffness with the help of transient elas-
tography26–32. Also, there are several studies that analyzed the predictive value of TE for esophageal varices and 
concluded that there is a significant correlation between TE values and the existence of esophageal varices33–37. 
However, in severe cirrhosis, the link between LSM and HVPG lessens as a result of cumulating factors, such as 
mechanical changes in the liver, mainly fibrosis, and the dynamic feature of PH (intrahepatic vasoconstriction and 
Any Esophageal 
Varices
Varices Needing 
Treatment (VNT)
AUROC (95% CI) 0.776 (0.698–0.853) 0.972 (0.944–1.000)
Balanced Cut-off
3 m/s:
79% Sensitivity;
67% Specificity;
80% PPV;
65% NPV;
2.39 LR + ;
0.31 LR-.
3.5 m/s:
93% Sensitivity;
86% Specificity;
64% PPV;
98% NPV;
6.64 LR + ;
0.08 LR-.
Rule In Cut-off
3.5 m/s:
47% Sensitivity;
96% Specificity;
80% PPV;
65% NPV;
11.75 LR + ;
0.55 LR-.
3.8 m/s:
55% Sensitivity;
98% Specificity;
89% PPV;
89% NPV;
27.5 LR + ;
0.46 LR-.
Rule Out Cut-off
2.5 m/s:
92% Sensitivity;
22% Specificity;
66% PPV;
61% NPV;
1.18 LR + ;
0.36 LR-.
3.2 m/s:
97% Sensitivity;
69% Specificity;
46% PPV;
99% NPV;
3.13 LR + ;
0.04 LR-.
Average Values 3.37 m/s 3.96 m/s
Table 2. The accuracy of spleen elastography.
Prevalence Sensitivity Specificity PPV NPV
50.0% 93.1% 0.0% 73.0% 0.0%
40.0% 93.1% 0.0% 64.3% 0.0%
30.0% 93.1% 31.8% 64.3% 77.8%
25.0% 93.1% 44.4% 64.3% 85.7%
20.0% 93.1% 57.1% 64.3% 90.9%
15.0% 93.1% 68.8% 64.3% 94.3%
10.0% 93.1% 79.7% 64.3% 96.7%
Table 3. Variation of accuracy for VNT based on different simulated prevalence.
Any Esophageal Varices Varices Needing Treatment (VNT)
OR [95% CI] p OR [95% CI] p
Aspartate Aminotransferase 0.998 [0.973–1.004] 0.134 0.997 [0.971–1.025] 0.851
Alanine Aminotransferase 1.015 [0.992–1.040] 0.209 1.008 [0.974–1.043] 0.651
Platelet Count 1.000 [1.000–1.000] 0.133 1.000 [1.000–1.000] 0.574
Spleen Diameter 1.033 [1.008–1.057] 0.009 1.021 [0.979–1.065] 0.337
Portal Vein Diameter 1.053 [0.813–1.363] 0.697 0.972 [0.548–1.722] 0.922
Hemoglobin 0.884 [0.633–1.234] 0.468 0.789 [0.511–1.218] 0.284
Spleen Elastography 3.976 [1.531–10.320] 0.005 1360.730 [34.183–54166.263] 0.000
Liver Elastography 1.468 [0.621–3.473] 0.382 0.955 [0.258–3.538] 0.945
Constant 0.01 0.038 0 0.003
AUROC = 0.845 [0.778–0.911]; 
Goodness of fit = 38.009, 
p < 0.001
AUROC = 0.974 [0.950–0.997]; 
Goodness of fit = 75.708, p < 0.001
Table 4. The multivariate analysis results.
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splanchnic vasodilation) that cannot be evaluated by TE38. A recent meta-analysis, that evaluated the performance 
of TE for detecting esophageal varices in cirrhotic patients, concluded that TE is not suitable for implementation 
in the clinical practice due to varying cut-off values and different etiologies39. The morphological changes of the 
spleen in portal hypertension, such as the vascular congestion angiogenesis, the lymphoid hyperplasia and the 
fibrosis have justified the use of spleen stiffness as another surrogate parameter of PH in cirrhosis40,41.
As a result, our study wanted to determine the predictive value of SSM measurement through virtual touch 
quantification, in the assessment of the existence and gravity of esophageal varices (EV) in patients suffering from 
cirrhosis of different etiologies. Upper digestive endoscopy was used as a comparison for the efficiency of this 
method. Spleen stiffness measurements were successfully carried out in all enrolled patients, resulting in a wide 
range of values that varied between 2.18 m/s and 4.77 m/s. The results showed a stepwise increase in splenic stiff-
ness with the increasing size of the varices (p < 0.001). The accuracy of SSM in predicting the presence of EV was 
demonstrated to be fair - good, with an AUROC of 0.776 and a good sensitivity and specificity (Se 72%, Sp 71%). 
The values for confirming or excluding the presence of the varices were: ≥ 3.50 m/s and < 2.50 m/s respectively. 
There are many studies that deemed the importance of spleen stiffness as being equivalent to that of the endos-
copy in predicting esophageal varices5,17,42. The majority of these used TE when performing SSM (TE-SSM)43–47.
There are at least two limitations for TE-SSM: the high percentage of failed measurements and the variability 
of the values with respect to the etiology of the liver diseases. In addition, there is one more limitation regarding 
the upper limit of the cut-off value of 75 kPa, considering that SSM frequently exceeds this value5,42,45,46.
There are several studies that performed ARFI for the assessment of spleen stiffness, alone10,18,48–50 or in com-
parison with TE5. Only two of those took HVPG as a reference for evaluating the spleen stiffness measurement 
performance51,52. Both of them revealed the remarkable accuracy of SSM in predicting clinically relevant portal 
pressure values. Most of the studies were aimed at evaluating the connection between SSM, measured through 
ARFI, and the presence and stage of the esophageal varices. As demonstrated in our study, there is a considerable 
correlation between ARFI-SSM and the existence of EVs in patients suffering from cirrhosis. Also, our study 
showed no significant differences between the optimal cut-off values of ARFI-SSM in predicting the existence of 
varices: 3.10 m/s48 3.18 m/s51/ 3.16 m/s5 and 3.02 m/s in our study. With regard to the performance of ARFI-SSM 
in predicting the severity of PH, expressed as the size of varices and the risk of bleeding, our results showed an 
excellent performance, AUROC = 0.972, in recognizing patients with varices needing treatment. The cut-off val-
ues of ARFI-SSM to rule out and rule in the varices at risk for bleeding were < 3.20 and ≥ 3.80 ms/s respectively. 
For a cut-off value of 3.20 m/s the predictive negative value is remarkable (99%) for excluding the cases with 
varices needing treatment. Another advantage of ARFI, underlined by all these studies, is the high feasibility of 
this method, without measurement failures like in the case of TE-SSM. However, there is one study that did not 
find ARFI-SSM to be a good parameter in evaluating the existence and gravity of EV53. On the other hand, the 
same group developed a predictive score that analyzed LSM and SSM, using ARFI measurements, in cirrhotic 
patients associating ascites, with a good accuracy in anticipating significant EV50.
One concern was raised regarding SSM as a complementary method in evaluating the existence of EVs in 
patients suffering from cirrhosis: the loss of correlation in alcohol induced cirrhosis49. Without a clear reason for 
this result, the authors have considered the smaller dimension of the spleen that characterized alcoholic cirrhosis 
to be a probable cause, as compared to viral or non-alcoholic steatohepatitis-cirrhosis. Our study did not con-
firm this hypothesis, because it found no differences between the diverse etiology of cirrhosis, including the one 
induced by alcohol (p = 0.301).
Another purpose of our study was to analyze the other parameters that were linked to the existence and sever-
ity of EV, in patients suffering from cirrhosis. In this regard, bivariate analysis showed a significant correlation, 
alongside SSM, of the platelet number, splenic size, portal vein diameter, AST values and ARFI - liver elasticity 
(p < 0.001). All these parameters were related not only to the presence and size of the varices, but also to the 
varices needing treatment. However, after multivariate analysis, SSM remained the only parameter that was highly 
associated with the presence and size of EVs and also with their risk of bleeding. There was another independent 
variable associated only with one, but not with all characteristics of esophageal varices: the splenic diameter 
used for detecting the presence of EV (p = 0.009). However, SSM was indisputably the strongest predictor for all 
endoscopic aspects of EV, from their presence, to the detection of varices needing treatment. Other studies also 
found ARFI-SSM to be a unique independent parameter for EV prediction, according to multivariate analysis48,49.
One limitation of our study is the uneven distribution of cirrhosis etiology, having only a few cases with 
NASH-cirrhosis, autoimmune and biliary cirrhosis. Therefore, it is difficult to assess the efficacy of splenic stiff-
ness in different etiologies of cirrhosis. Another limitation is the lack of a standard protocol for performing 
the measurements for spleen stiffness. Usually, the measurements were made 2 cm under the splenic capsule, 
Any Esophageal 
Varices
Varices Needing 
Treatment (VNT) Overall
Alcoholic 3.47 m/s 4.04 m/s 3.31 m/s
Hepatitis B 3.05 m/s 3.67 m/s 2.97 m/s
Hepatitis C 3.40 m/s 3.94 m/s 3.14 m/s
Other 3.63 m/s 4.15 m/s 3.05 m/s
Test Independent Samples Kruskal-Wallis
Independent Samples 
Kruskal-Wallis
Independent Samples 
Kruskal-Wallis
p-value 0.078 0.383 0.301
Table 5. Assessment of differences between different etiologies of cirrhosis.
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mostly in the middle part of the spleen. In the study of Rizo et al.41 the measurements were extensively performed 
throughout the entire splenic parenchyma, in order to be more representative.
However, we consider that ARFI spleen stiffness measurement is an optimal method to use in the clinical 
practice, for the screening of cirrhotic patients, for esophageal varices. By easily and reliably diagnosing high-risk 
varices, ARFI can discriminate variceal bleeders from non-bleeders. We believe that our study may contribute 
to recognizing splenic stiffness as a novel parameter and an unlimited tool for gastroenterologists to use in the 
screening of the cirrhotic population, reducing the number of endoscopic examinations and, as a result, improv-
ing the Baveno VI criteria.
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